These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 9811500)

  • 41. Immunization against leishmaniasis by PLGA nanospheres loaded with an experimental autoclaved Leishmania major (ALM) and Quillaja saponins.
    Tafaghodi M; Eskandari M; Kharazizadeh M; Khamesipour A; Jaafari MR
    Trop Biomed; 2010 Dec; 27(3):639-50. PubMed ID: 21399606
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytoplasmic delivery of a macromolecular fluorescent probe by poly(d, l-lactic-co-glycolic acid) microspheres.
    Newman KD; Kwon GS; Miller GG; Chlumecky V; Samuel J
    J Biomed Mater Res; 2000 Jun; 50(4):591-7. PubMed ID: 10756318
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Antigen-specific killer polylactic-co-glycolic acid (PLGA) microspheres can prolong alloskin graft survival in a murine model.
    Wang W; Fang K; Wang X; Li M; Wu Y; Chen F; Shahzad KA; Gu N; Shen C
    Immunol Invest; 2015; 44(4):385-99. PubMed ID: 25942349
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Toward a Single-Dose Vaccination Strategy with Self-Encapsulating PLGA Microspheres.
    Bailey BA; Ochyl LJ; Schwendeman SP; Moon JJ
    Adv Healthc Mater; 2017 Jun; 6(12):. PubMed ID: 28371568
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Poly(D,L lactic-co-glycolic acid) microspheres as biodegradable microcarriers for pluripotent stem cells.
    Newman KD; McBurney MW
    Biomaterials; 2004 Nov; 25(26):5763-71. PubMed ID: 15147822
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Modulation of the immune response to tetanus toxoid by polylactide-polyglycolide microspheres.
    Walker KB; Xing DK; Sesardic D; Corbel MJ
    Dev Biol Stand; 1998; 92():259-67. PubMed ID: 9554281
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biodegradable PLGA microspheres as a delivery system for malaria synthetic peptide SPf66.
    Rosas JE; Hernández RM; Gascón AR; Igartua M; Guzman F; Patarroyo ME; Pedraz JL
    Vaccine; 2001 Aug; 19(31):4445-51. PubMed ID: 11483270
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Designing improved poly lactic-co-glycolic acid microspheres for a malarial vaccine: incorporation of alginate and polyinosinic-polycytidilic acid.
    Salvador A; Igartua M; Hernández RM; Pedraz JL
    J Microencapsul; 2014; 31(6):560-6. PubMed ID: 24697189
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of a single-dose stabilized poly(D,L-lactic-co-glycolic acid) microspheres-based vaccine against hepatitis B.
    Jaganathan KS; Singh P; Prabakaran D; Mishra V; Vyas SP
    J Pharm Pharmacol; 2004 Oct; 56(10):1243-50. PubMed ID: 15482638
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Potent, long lasting systemic antibody levels and mixed Th1/Th2 immune response after nasal immunization with malaria antigen loaded PLGA microparticles.
    Carcaboso AM; Hernández RM; Igartua M; Rosas JE; Patarroyo ME; Pedraz JL
    Vaccine; 2004 Mar; 22(11-12):1423-32. PubMed ID: 15063565
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Multiple antigen peptide consisting of B- and T-cell epitopes of F1 antigen of Y. pestis showed enhanced humoral and mucosal immune response in different strains of mice.
    Ali R; Kumar S; Naqvi RA; Sheikh IA; Rao DN
    Int Immunopharmacol; 2013 Jan; 15(1):97-105. PubMed ID: 23174507
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Enhancing immunogenicity and reducing dose of microparticulated synthetic vaccines: single intradermal administration.
    Carcaboso AM; Hernández RM; Igartua M; Rosas JE; Patarroyo ME; Pedraz JL
    Pharm Res; 2004 Jan; 21(1):121-6. PubMed ID: 14984266
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vivo evidence of oral vaccination with PLGA nanoparticles containing the immunostimulant monophosphoryl lipid A.
    Sarti F; Perera G; Hintzen F; Kotti K; Karageorgiou V; Kammona O; Kiparissides C; Bernkop-Schnürch A
    Biomaterials; 2011 Jun; 32(16):4052-7. PubMed ID: 21377204
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protective efficacy of PLGA microspheres loaded with divalent DNA vaccine encoding the ompA gene of Aeromonas veronii and the hly gene of Aeromonas hydrophila in mice.
    Gao S; Zhao N; Amer S; Qian M; Lv M; Zhao Y; Su X; Cao J; He H; Zhao B
    Vaccine; 2013 Nov; 31(48):5754-9. PubMed ID: 24012571
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Administration routes affect the quality of immune responses: A cross-sectional evaluation of particulate antigen-delivery systems.
    Mohanan D; Slütter B; Henriksen-Lacey M; Jiskoot W; Bouwstra JA; Perrie Y; Kündig TM; Gander B; Johansen P
    J Control Release; 2010 Nov; 147(3):342-9. PubMed ID: 20727926
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Microsphere priming facilitates induction of potent therapeutic T-cell immune responses against autochthonous liver cancers.
    Brinkhoff B; Ostroumov D; Heemcke J; Woller N; Gürlevik E; Manns MP; Longerich T; Zender L; Harty JT; Kubicka S; Kühnel F; Wirth TC
    Eur J Immunol; 2014 Apr; 44(4):1213-24. PubMed ID: 24338782
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of the physical form of poly(lactic-co-glycolic acid) carriers on the humoral immune response to co-delivered antigen.
    Bennewitz NL; Babensee JE
    Biomaterials; 2005 Jun; 26(16):2991-9. PubMed ID: 15603794
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of surface charge of PLGA particles of recombinant hepatitis B surface antigen in enhancing systemic and mucosal immune responses.
    Thomas C; Gupta V; Ahsan F
    Int J Pharm; 2009 Sep; 379(1):41-50. PubMed ID: 19524654
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lactic acid triggers, in vitro, thiomersal to degrade protein in the presence of PLGA microspheres.
    Namur JA; Takata CS; Moro AM; Politi MJ; De Araujo PS; Cuccovia IM; Da Costa MH
    Int J Pharm; 2004 Apr; 273(1-2):1-8. PubMed ID: 15010124
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunogenicity and antitumor activity of a liposomal MUC1 peptide-based vaccine.
    Samuel J; Budzynski WA; Reddish MA; Ding L; Zimmermann GL; Krantz MJ; Koganty RR; Longenecker BM
    Int J Cancer; 1998 Jan; 75(2):295-302. PubMed ID: 9462722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.